Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus

Neurology

Volumn 54, Issue 5, 2000, Pages 1132-1138

  Sainio, Markku ^a   Jaaskelainen J ^b   Pihlaja, H ^b   Carpen O ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

Genotype; Merlin; Neurofibromatosis 2; Phenotype; Schwannoma; Splice donor mutation

Indexed keywords

DNA; MERLIN; RNA;

ADOLESCENT; ADULT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FAMILIAL DISEASE; FEMALE; GENE MUTATION; GENETIC LINKAGE; GENOTYPE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEURILEMOMA; NEUROFIBROMATOSIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR SUPPRESSOR GENE;

EID: 0343851630     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.5.1132     Document Type: Article

References (36)

1. Gutmann DH. Molecular insights into neurofibromatosis 2. Neurobiol Dis 1997;3:247-261.
2. Eldridge R. Central neurofibromatosis with bilateral acoustic neuroma. Adv Neurol 1981;29:57-65.
3. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-618.
4. Sainio M, Strachan T, Blomstedt G, et al. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree. Neurology 1995;45: 1314-1322.
5. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-521.
6. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800.
7. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995;92:10854-10858.
8. Gutmann DH, Wright DE, Geist RT, Snider WD. Expression of the neurofibromatosis 2 (NF2) gene isoforms during rat embryonic development. Hum Mol Genet 1995;4:471-478.
9. Arakawa H, Hayashi N, Nagase H, Ogawa M, Nakamura Y. Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum Mol Genet 1994;3:565-568.
10. Pykett MJ, Murphy M, Harnish PR, George DL. The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcripts. Hum Mol Genet 1994;3:559-564.
11. Sainio M, Zhao F, Heiska L, et al. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci 1997;110: 2249-2260.
12. Vaheri A, Carpén O, Heiska L, et al. The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol 1997;9:659-666.
13. Bretscher A. Regulation of cortical structure by the ezrinradixin-moesin protein family. Curr Opin Cell Biol 1999;11: 109-116.
14. Grönholm M, Sainio M, Zhao F, Heiska L, Vaheri A, Carpén O. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J Cell Sci 1999;112:895-904.
15. Merel P, Hoang-Xuan K, Sanson M, et al. Screening for germline mutations in the NF2 gene. Genes Chromosom Cancer 1995;12:117-127.
16. Kluwe L, Bayer S, Baser ME, et al. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet 1996;98:534-538.
17. Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59:529-539.
18. Ruttledge MH, Andermann AA, Phelan CM, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-342.
19. Evans DG, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 1998;35:450-455.
20. Kluwe L, MacCollin M, Tatagiba M, et al. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet 1998;77:228-233.
21. MacCollin M, Ramesh V, Jacoby LB, et al. Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 1994;55:314-320.
22. Jacoby LB, MacCollin M, Barone R, Ramesh V, Gusella JF. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosom Cancer 1996;17:45-55.
23. Suomalainen A, Syvänen AC. Analysis of nucleotide sequence variations by solid-phase minisequencing. Method Mol Biol 1996;65:73-79.
24. den Bakker MA, Riegman PH, Hekman RA, et al. The product of the NF2 tumour suppressor gene localizes near the plasma membrane and is highly expressed in muscle cells. Oncogene 1995;10:757-763.
25. Lutchman M, Rouleau GA. The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res 1995;55:2270-2274.
26. Bourn D, Strachan T. Dinucleotide repeat polymorphism at the NF2 gene. Hum Mol Genet 1994;3:813-816.
27. Antinheimo J, Haapasalo H, Seppälä M, Sainio M, Carpén O, Jääskeläinen J. Proliferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling. J Neuropathol Exp Neurol 1995; 54:776-782.
28. Syvänen AC, Aalto-Setälä K, Harju L, Kontula K, Söderlund H. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics 1990;8:684-692.
29. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992;90: 41-54.
30. Dominski Z, Kole R. Selection of splice sites in pre-mRNAs with short internal exons. Mol Cell Biol 1991;11:6075-6083.
31. Kluwe L, Pulst SM, Koppen J, Mautner VF. A 163-bp deletion in the neurofibromatosis 2 (NF2) gene associated with variant phenotypes. Hum Genet 1995;95:443-446.
32. Gutmann DH, Giordano MJ, Fishback AS, Guha A. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 1997;49:267-270.
33. Huynh DP, Mautner V, Baser ME, Stavrou D, Pulst SM. Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas. J Neuropathol Exp Neurol 1997;56:382-390.
34. Harwalkar JA, Lee JH, Hughes G, Kinney SE, Golubic M. Immunoblotting analysis of schwannomin/merlin in human schwannomas. Am J Otol 1998;19:654-659.
35. Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, et al. Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol 1997;151:1649-1654.
36. Sherman L, Xu HM, Geist RT, et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 1997;15:2505-2509.